We are live on ! Find out more
VRTX icon

Vertex Pharmaceuticals
VRTX

479 hedge funds and large institutions have $27.5B invested in Vertex Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 194 increasing their positions, 155 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 47

25% more repeat investments, than reductions

Existing positions increased: 194 | Existing positions reduced: 155

1% more funds holding

Funds holding: 474 → 479 (+5)

1% more capital invested

Capital invested by funds: $27.3B → $27.5B (+$279M)

17% less call options, than puts

Call options by funds: $80.4M | Put options by funds: $97.3M

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

Holders
479
Holders Change
+5
Holders Change %
+1.05%
% of All Funds
12.77%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.11%
New
62
Increased
194
Reduced
155
Closed
47
Calls
$80.4M
Puts
$97.3M
Net Calls
-$16.9M
Net Calls Change
+$182M

Top Buyers

1
MCM
Marsico Capital Management
Colorado
+$259M
2
Winslow Capital Management
Winslow Capital Management
Minnesota
+$222M
3
UBS AM
UBS AM
Illinois
+$157M
4
Viking Global Investors
Viking Global Investors
Connecticut
+$121M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$113M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$238M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$220M
3
O
OrbiMed
New York
-$191M
4
Capital World Investors
Capital World Investors
California
-$139M
5
Millennium Management
Millennium Management
New York
-$79.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
WCM
476
Wealthcare Capital Management
Virginia
$2K +$1.68K +14 New
AT
477
Arden Trust
Delaware
$1.07K +$219K +1,826 +25%
HR
478
Howe & Rusling
New York
$1K – – –
MA
479
MUFG Americas
New York
$1K – – –
1832 Asset Management
480
1832 Asset Management
Ontario, Canada
– -$78.4M -668,900 Closed
PA
481
Perceptive Advisors
New York
– -$13.1M -110,000 Closed
CC
482
Carlson Capital
Texas
– -$9.91M -82,700 Closed
BFIC
483
Bedell Frazier Investment Counselling
California
– -$4.72M -39,770 Closed
MLL
484
Moody Lynn & Lieberson
Massachusetts
– -$4.32M -36,390 Closed
Group One Trading
485
Group One Trading
Illinois
– -$3.64M -30,402 Closed
SFM
486
Sphera Funds Management
Israel
– -$3.56M -30,000 Closed
HT
487
HAP Trading
New York
– -$2.99M -24,922 Closed
PL
488
Perpetual Ltd
Australia
– -$2.83M -23,793 Closed
Capital Fund Management (CFM)
489
Capital Fund Management (CFM)
France
– -$2.51M -21,162 Closed
QIM
490
Quantitative Investment Management
Virginia
– -$2.36M -19,900 Closed
BACM
491
Blue Arrow Capital Management
New York
– -$2.15M -18,138 Closed
HMS
492
Hanseatic Management Services
New Mexico
– -$2M -16,849 Closed
SGH
493
Sivik Global Healthcare
Connecticut
– -$1.77M -14,900 Closed
QSS
494
Quantitative Systematic Strategies
Florida
– -$1.35M -11,323 Closed
DIA
495
Denver Investment Advisors
Colorado
– -$1.26M -10,637 Closed
ACM
496
Atika Capital Management
New York
– -$1.13M -9,500 Closed
SPC
497
Sigma Planning Corp
Michigan
– -$1.01M -8,483 Closed
TH
498
Timber Hill
Connecticut
– -$1.01M -8,396 Closed
BCM
499
Barometer Capital Management
Ontario, Canada
– -$808K -6,800 Closed
Tudor Investment Corp
500
Tudor Investment Corp
Connecticut
– -$783K -6,589 Closed
17 18 19
20
21

VRTX Hedge Fund Activity: Q1 2015 in Review

479 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2015, worth a combined $27.5B — up 1% from $27.3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new VRTX positions and 47 closed out — a net gain of 15 holders — while 194 added to existing stakes and 155 trimmed.

The largest buyer was Marsico Capital Management, opening a new position worth an estimated $259M. The largest seller was Vanguard Group, cutting an estimated $238M.

  • 479 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2015, up from 474 in Q4 2014.
  • Funds reported $27.5B of Vertex Pharmaceuticals stock for Q1 2015, up 1% quarter-over-quarter.
  • 62 funds opened new Vertex Pharmaceuticals positions in Q1 2015 and 47 closed out, a net change of +15 holders.
  • The largest Vertex Pharmaceuticals buyer in Q1 2015 was Marsico Capital Management, an estimated $259M added.
  • The largest Vertex Pharmaceuticals seller in Q1 2015 was Vanguard Group, an estimated $238M sold.

Based on aggregated 13F filings for Q1 2015.